Clinical Trial Update: A Study of Mogamulizumab to Prevent Adult T-cell Leukemia/Lymphoma in People With HTLV-1 [Phase 2]

View source ↗

Summary

Phase 2 trial of mogamulizumab to prevent adult T-cell leukemia/lymphoma in HTLV-1–infected individuals; currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• T-cell Leukemia Lymphoma

Drugs mentioned

• Mogamulizumab (mogamulizumab)

Snippet

Sponsor: Memorial Sloan Kettering Cancer Center | Conditions: T-Cell Leukemia/Lymphoma, Adult, T-cell Leukemia/Lymphoma | Phase 2 | Status: RECRUITING